Secure CheckoutPersonal information is secured with SSL technology.
Free ShippingFree global shipping
No minimum order.
List of figures and tables
List of abbreviations
About the author
Chapter 1: Introduction
1.1 The emergence of global pharmaceutical linkage
1.2 Canadian pharmaceutical linkage regulations
Chapter 2: Background: drug approval, drug patenting, pharmaceutical linkage, and public health policy
2.1 Drug approval
2.3 Linkage regulations
2.4 IPR rights and innovation policy
Chapter 3: Empirical analysis of drug approval
3.5 Interpretation of data
3.6 Study limitations
3.7 Assessing the lifecycle approach: the long view
3.8 Government as representative public agent
3.9 Summary and conclusions
Chapter 4: Empirical analysis of pharmaceutical innovation and drug approval-drug patenting linkage
Chapter 5: Empirical analysis of drug patenting in multiple high-value cohorts
5.5 Summary and conclusions
Chapter 6: Implications of empirical data: are pharmaceutical linkage regulations a success?
6.2 Debate preceding Bill C-91
6.3 ‘Original policy intent’
6.4 ‘Patent-specific’ analysis
6.5 Statutory interpretation
6.6 Revisiting the empirical data
6.7 Summary and conclusions
Chapter 7: Future directions: testable hypotheses and evolution toward global pharmaceutical linkage
7.1 Hypotheses regarding cluster-based drug development
7.2 Globalization of pharmaceutical linkage
Patently innovative provides a review of the importance of traditional patent law and emerging linkage regulations for pharmaceutical products on the global stage, with a focus on the linkage regime in Canada. The primary focus is on how innovation in the pharmaceutical sector can be strongly regulated and how government regulation can either stimulate or inhibit development of breakthrough products.
- Includes empirical research to relate innovation to drug law
- A multidisciplinary approach is taken, including the intersection of IP (intellectual property) law, drug law and innovation
- Discusses the impact of government regulation on firm innovation
Patent attorneys and intellectual property personnel at pharmaceutical and biotechnology companies
- No. of pages:
- © Woodhead Publishing 2012
- 2nd January 2012
- Woodhead Publishing
- Hardcover ISBN:
- eBook ISBN:
Dr Ron A. Bouchard is an intellectual property lawyer and scholar, specializing in the innovation, regulation, and litigation of biomedical products. His career has focused on the science, law, policy, regulation, and commercialization of medical technologies. He began his career as a medical scientist, completing a PhD and Postdoctoral Fellowship in the field of ion channel biophysics and Ca2+ imaging. He shifted focus to obtain a law degree specializing in pharmaceutical and biotechnology law and has been involved in the prosecution, acquisition, financing, distribution, and litigation of intellectual property rights. Dr Bouchard has appeared before the Federal Court of Canada and the Supreme Court of Canada. He has consulted with firms, universities, governments, and international organizations on legal, regulatory, and policy issues. He worked with the Government of Canada on its platforms for drug regulation and public private partnerships in technology commercialization. His research has been funded by federal and provincial funding agencies and private endowments. His scholarly expertise is focused on the intellectual property and regulatory aspects of therapeutic product development, including global aspects of technology commercialization, patenting, licensing, and regulatory approval, and empirical assessment of the impact of government stimulus packages and regulation on technology innovation. Dr Bouchard currently is involved with a new global consortium of scholars, physicians and economists studying the impact of emerging forms of patent law on the availability and costs of essential medications in developed and developing nations: the Consortium Study of Global Pharmaceutical Linkage.
Intellectual Property Lawyer and Scholar, Canada
Elsevier.com visitor survey
We are always looking for ways to improve customer experience on Elsevier.com.
We would like to ask you for a moment of your time to fill in a short questionnaire, at the end of your visit.
If you decide to participate, a new browser tab will open so you can complete the survey after you have completed your visit to this website.
Thanks in advance for your time.